Vaccine Side Effects, also known as adverse events following immunization (AEFI), are potential reactions that may occur after receiving a vaccine. It's important to note that most vaccine side effects are mild and temporary, such as soreness at the injection site, low-grade fever, or mild fatigue. These reactions are typically short-lived and resolve on their own without any long-term consequences. However, vaccines, like any medical intervention, can occasionally cause more serious side effects, although these are rare. Severe allergic reactions, known as anaphylaxis, can occur shortly after vaccination but are extremely rare, occurring in approximately 1 in every million vaccine doses administered. Symptoms of anaphylaxis may include difficulty breathing, swelling of the face or throat, rapid heartbeat, and dizziness, and require immediate medical attention.
Other rare but serious side effects associated with specific vaccines include febrile seizures, Guillain-Barré Syndrome (GBS), and acute disseminated encephalomyelitis (ADEM). These adverse events are closely monitored by public health authorities and vaccine safety surveillance systems to detect any potential signals or patterns and ensure the ongoing safety of vaccines. It's essential to emphasize that the benefits of vaccination far outweigh the risks of potential side effects. Vaccines have been rigorously tested in clinical trials to ensure their safety and efficacy before being approved for use. Additionally, extensive post-marketing surveillance systems continuously monitor vaccine safety to detect and investigate any adverse events that may occur after vaccination. The vast majority of vaccine side effects are mild and transient, and the risk of serious adverse events is extremely low. The benefits of vaccination in preventing serious and potentially life-threatening diseases, reducing the spread of infectious pathogens, and protecting individuals and communities far outweigh the risk of adverse events.
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey
Title : Overcoming biophysical characterization challenges of small antigens in dilute vaccine formulations
Eric Kemp, Merck & Co., United States
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : A combined LC-MS and immunoassay approach to characterize preservative-induced destabilization of human papillomavirus virus-like particles adsorbed to an aluminum-salt adjuvant
Ria T Caringal, University of Kansas, United States